Skip to main content

Innovative Automated Insulin Delivery System for Type 2 Diabetes

Completed · Not applicable · NCT06853990

Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

At a glance

Research payments reported, 2025
$4.2M
U.S. investigators named
30
Sites paid
30
Planned or actual enrollment
307

About the trial

Sponsor
Deka Research and Development (with Sequel Med Tech)
Tested
twiist insulin delivery system (device)
Dates
Started 2025-04-14; completion 2026-05-06
Results posted
Not yet

The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.

From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sequel Med Tech, LLC reported $4.2M in research payments for this study in 2025 (3,746 payments).

Products named: Twiist

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.